FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1
Preeti Narayan(Center for Drug Evaluation and Research), Julia A. Beaver(Center for Drug Evaluation and Research), Shyam Kalavar(Center for Devices and Radiological Health), Amna Ibrahim(Beni-Suef University), Soma Ghosh(Center for Devices and Radiological Health), Reena Philip(Center for Devices and Radiological Health), Gideon M. Blumenthal(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yuan Xu(Harbin Medical University), Wentao Fu(Center for Drug Evaluation and Research), Sherry Hou(Center for Drug Evaluation and Research), Shenghui Tang(United States Food and Drug Administration), Bellinda L. King‐Kallimanis(LUNGevity Foundation), Jennifer Gao(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Sakar Wahby(Center for Drug Evaluation and Research), Paul G. Kluetz(United States Food and Drug Administration), Laleh Amiri‐Kordestani(United States Food and Drug Administration), Pengfei Song(Henan University), Marc R. Theoret(United States Food and Drug Administration), Kirsten B. Goldberg(United States Food and Drug Administration), Jiang Liu(Guangdong Medical College), Yutao Gong(Center for Drug Evaluation and Research), Rajeshwari Sridhara(Center for Drug Evaluation and Research), Erik Bloomquist(Center for Drug Evaluation and Research)
Cited by 185
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k